Eli Lilly’s Mounjaro (tirzepatide) continues to drive outsized revenue growth amid robust demand for GLP-1 therapies. Worldwide sales reached $8.7 billion in Q1 2026, up 125% year-over-year, with U.S. volume expanding sharply even as realized prices declined in the low- to mid-teens percent range due to rebates and formulary shifts. International expansion, including China NRDL inclusion, added meaningful contribution. Analysts project Q2 2026 company revenue near $20.5 billion, implying sustained momentum for the tirzepatide franchise ahead of the late-July earnings release. Key variables include prescription trends, supply availability, competitive pressure from Novo Nordisk, and any one-time pricing adjustments that could influence the final reported figure relative to market-implied thresholds.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · ОбновленоНОВОЕ
5 авг. 2026 г.
$7,5 млрд
96%
$8,25 млрд
91%
$9 млрд
86%
$9,75 млрд
39%
$10,5 млрд
11%
$463 Объем
$7,5 млрд
$40 Объем
96%
$8,25 млрд
$120 Объем
91%
$9 млрд
$81 Объем
86%
$9,75 млрд
$121 Объем
39%
$10,5 млрд
$101 Объем
11%
This market will resolve to "Yes" if Eli Lilly's Mounjaro total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.Eli Lilly’s Mounjaro (tirzepatide) continues to drive outsized revenue growth amid robust demand for GLP-1 therapies. Worldwide sales reached $8.7 billion in Q1 2026, up 125% year-over-year, with U.S. volume expanding sharply even as realized prices declined in the low- to mid-teens percent range due to rebates and formulary shifts. International expansion, including China NRDL inclusion, added meaningful contribution. Analysts project Q2 2026 company revenue near $20.5 billion, implying sustained momentum for the tirzepatide franchise ahead of the late-July earnings release. Key variables include prescription trends, supply availability, competitive pressure from Novo Nordisk, and any one-time pricing adjustments that could influence the final reported figure relative to market-implied thresholds.
This market will resolve to "Yes" if Eli Lilly's Mounjaro total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Открытие рынка: Jul 27, 2026, 1:43 PM ET
Объем
$463Дата окончания
5 авг. 2026 г.Открытие рынка
Jul 27, 2026, 1:43 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if Eli Lilly's Mounjaro total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.Eli Lilly’s Mounjaro (tirzepatide) continues to drive outsized revenue growth amid robust demand for GLP-1 therapies. Worldwide sales reached $8.7 billion in Q1 2026, up 125% year-over-year, with U.S. volume expanding sharply even as realized prices declined in the low- to mid-teens percent range due to rebates and formulary shifts. International expansion, including China NRDL inclusion, added meaningful contribution. Analysts project Q2 2026 company revenue near $20.5 billion, implying sustained momentum for the tirzepatide franchise ahead of the late-July earnings release. Key variables include prescription trends, supply availability, competitive pressure from Novo Nordisk, and any one-time pricing adjustments that could influence the final reported figure relative to market-implied thresholds.
This market will resolve to "Yes" if Eli Lilly's Mounjaro total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Объем
$463Дата окончания
5 авг. 2026 г.Открытие рынка
Jul 27, 2026, 1:43 PM ETResolver
0x65070BE91...Eli Lilly’s Mounjaro (tirzepatide) continues to drive outsized revenue growth amid robust demand for GLP-1 therapies. Worldwide sales reached $8.7 billion in Q1 2026, up 125% year-over-year, with U.S. volume expanding sharply even as realized prices declined in the low- to mid-teens percent range due to rebates and formulary shifts. International expansion, including China NRDL inclusion, added meaningful contribution. Analysts project Q2 2026 company revenue near $20.5 billion, implying sustained momentum for the tirzepatide franchise ahead of the late-July earnings release. Key variables include prescription trends, supply availability, competitive pressure from Novo Nordisk, and any one-time pricing adjustments that could influence the final reported figure relative to market-implied thresholds.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · ОбновленоСвязанные
Будет ли общий объем поставок отечественных сигарет Altria (MO) во 2 квартале (штуки в миллионах) выше 14 млн?
95%
Да
Будет ли выручка подразделения рейтингов S&P Global (SPGI) за второй квартал выше $13 млрд?
2%
Да
Будет ли выручка Advanced Micro Devices (AMD) от дата-центров во 2-м квартале выше $6,25 млрд?
90%
Да
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы